

Jindřich Kopecký^{1/2}

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577560/publications.pdf>

Version: 2024-02-01

35
papers

390
citations

933447

10
h-index

794594

19
g-index

36
all docs

36
docs citations

36
times ranked

765
citing authors

#	ARTICLE	IF	CITATIONS
1	The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 295-307.	3.3	99
2	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 262.	0.8	44
3	Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 381-384.	1.3	28
4	Microsatellite instability in melanoma: a comprehensive review. <i>Melanoma Research</i> , 2016, 26, 545-550.	1.2	26
5	Neoadjuvant chemoradiotherapy of rectal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 632-640.	2.0	22
6	Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 452-457.	2.0	21
7	Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. <i>Wspolczesna Onkologia</i> , 2015, 4, 290-299.	1.4	21
8	MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 353-359.	2.0	17
9	Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. <i>Medical Hypotheses</i> , 2016, 93, 74-76.	1.5	14
10	Dermatomyositis with anti-TIF-1 ^β antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. <i>BMC Cancer</i> , 2016, 16, 684.	2.6	12
11	Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response. <i>Anticancer Research</i> , 2018, 38, 2961-2965.	1.1	11
12	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. <i>BMC Cancer</i> , 2017, 17, 880.	2.6	10
13	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. <i>Cancers</i> , 2020, 12, 808.	3.7	10
14	Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. <i>Frontiers in Oncology</i> , 2020, 10, 575148.	2.8	9
15	Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2015, 159, 695-697.	0.6	8
16	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1047-e1053.	1.9	7
17	Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2018, 162, 335-339.	0.6	6
18	Cutaneous Recurrence of Malignant Mesothelioma of the Tunica Vaginalis Testis: a Rare Case Report. <i>Onkologie</i> , 2012, 35, 46-48.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 294.e1-294.e8.	1.6	4
20	Failure of adjuvant treatment for malignant melanoma – what next?. <i>Klinicka Onkologie</i> , 2021, 34, 73-77.	0.3	4
21	Immunotherapy related toxicities. <i>Onkologie (Czech Republic)</i> , 2017, 11, 83-87.	0.1	3
22	Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2022, 166, 393-404.	0.6	2
23	Percutaneous biopsy of retroperitoneal lesions - 10 year experience of a single centre. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020, 164, 435-443.	0.6	2
24	Tamoxifen and arrhythmia. <i>Medical Oncology</i> , 2010, 27, 1431-1432.	2.5	1
25	Palliative care among elderly cancer patients: Own experience. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 49-52.	0.6	1
26	Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. <i>In Vivo</i> , 2021, 35, 2981-2990.	1.3	1
27	Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer. <i>Current Oncology</i> , 2021, 28, 2914-2927.	2.2	1
28	Effect of Depressive Mood on NK Cells in Patients with Pancreatic Tumor – Pilot Study. <i>British Journal of Medicine and Medical Research</i> , 2016, 14, 1-8.	0.2	1
29	Our experiences in the treatment of peripheral primitive neuroectodermal tumour in the years 2000-2010 in the Cancer Centre in Hradec Králová. <i>Wspolczesna Onkologia</i> , 2011, 4, 203-207.	1.4	0
30	Extravasation of doxorubicin – a dreaded complication of therapy. <i>Wspolczesna Onkologia</i> , 2014, , .	1.4	0
31	Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , 2021, 13, 4591.	3.7	0
32	PROGRAM OF PALLIATIVE CANCER CARE – OUR EXPERIENCE. <i>Acta Medica (Hradec Kralove)</i> , 2013, 56, 29-32.	0.5	0
33	How to manage side effects of immunotherapy. <i>Onkologie (Czech Republic)</i> , 2020, 14, 6-12.	0.1	0
34	Adverse effects of targeted cancer treatment. <i>Onkologie (Czech Republic)</i> , 2020, 14, 18-23.	0.1	0
35	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. <i>Onkologie (Czech Republic)</i> , 2020, 14, 199-204.	0.1	0